Fig. 1 · Structure

Documents & Downloads

Hyperoside

Cat. No. A12070 CAS 482-36-0
Hyperoside protects against peroxide-induced oxidative damage to cells by scavenging reactive oxygen species and enhancing activity of anti-oxidant enzymes, in particular, catalase and glutathione peroxidase.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 10 μg/mL Cytotoxicity against human A549 cells by MTT assay [PMID: 25862199]
C2C12 EC50 60.5 μM Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting [PMID: 22738356]
HeLa IC50 > 10 μg/mL Cytotoxicity against human HeLa cells by MTT assay [PMID: 25862199]
RAW264.7 IC50 > 50 μM Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA [PMID: 24679441]
RAW264.7 IC50 48.8 μM Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis [PMID: 24679441]
SGC-7901 IC50 > 10 μg/mL Cytotoxicity against human SGC7901 cells by MTT assay [PMID: 25862199]

Hyperoside Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Hyperoside from 3 published references. In vitro models include K562 cells; MCF-7 cells.

Hyperoside In Vitro Studies

In K562 cells, Hyperoside treatment at 2 mM was associated with gene downregulation and upregulation relative to the control group. In MCF-7 cells, viability following Hyperoside exposure showed a time- and concentration-dependent pattern. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Gene expression changes in K562 cells

Cell-based study · K562 cells [1]

In K562 cells, Hyperoside treatment at 2 mM was associated with both downregulation and upregulation of genes relative to the control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
differentially expressed genesdifferentially expressed genes 2 mM: downregulation and upregulation of 605 and 1,033 genes[1]

Literature-Reported Treatment Conditions

Treatment concentration
2 mM
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Hyperoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Hyperoside induces ferroptotic CML cell death (S59, S61); Fig. 2 legend (S111)

differentially expressed genes: differentially expressed genes; comparator: control group — Results > Hyperoside induces ferroptotic CML cell death (S59, S61); Fig. 2 legend (S111)

Time and concentration dependence of cell viability

Cell-based study · MCF-7 cells [2]

In MCF-7 cells exposed to Hyperoside, cell viability showed a time- and concentration-dependent pattern.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result hyperoside (50 μM) according to different time periods (6, 12, or 24 h); different concentrations of hyperoside (12.5, 25, 50, 75, or 100 μM) for 24 h: Considering the cell viability after the treatment of hyperoside, a time- and concentration-dependent pattern was shown.[2]

Literature-Reported Treatment Conditions

Treatment concentration
12.5, 25, 50, 75, or 100 μM
Exposure duration
hyperoside (50 μM) according to different time periods (6, 12, or 24 h); different concentrations of hyperoside (12.5, 25, 50, 75, or 100 μM) for 24 h
Method
exposed to different concentrations of hyperoside
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Hyperoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Effects of Hyperoside on Cell Viability (S3, S4); 4. Materials and Methods > 4.3. Cell Viability Assay (S41, S42, S43); Figure 1 legend (S98)

cell viability: cell viability; comparator: normal control group — 2. Results > 2.1. Effects of Hyperoside on Cell Viability (S3, S4); 4. Materials and Methods > 4.3. Cell Viability Assay (S42)

Hyperoside In Vivo Studies

In Balb/c mice with subcutaneous homotransplants, Hyperoside significantly reduced average tumor volume compared with the saline control group. In male Balb/c mice with adriamycin-induced nephropathy, Hyperoside treatment reduced albuminuria compared with the ADR group. [2,3]

Reduced tumor volume in a mouse homotransplant model

Animal study · Balb/c mice; subcutaneous homotransplant mouse model; n = 5 per group [2]

In Balb/c mice with subcutaneous homotransplants, Hyperoside treatment at 50 mg/kg for 18 days significantly reduced average tumor volume compared with the saline control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor volumeReported result Hyperoside (50 mg/kg i.p. every two day for 18 days): compared to the control group, the average tumor volume in the hyperoside-treated group was significantly reduced.[2]

Conditions shared by the study groups

Route
i.p.; drugs were injected into the tumor
Treatment course
every two day for 18 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Hyperoside 50 mg/kgsaline as the control groupHyperoside (50 mg/kg i.p. every two day for 18 days): compared to the control group, the average tumor volume in the hyperoside-treated group was significantly reduced.[2]
Hyperoside 50 mg/kg
Model: Balb/c mice; subcutaneous homotransplant mouse model; n = 5 per group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Hyperoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.5. Hyperoside Can Inhibit the Growth of Breast Tumor (S28, S29); 4. Materials and Methods > 4.10. In Vivo Experiment (S80, S83, S84, S85, S86); Figure 5 legend (S122, S123)

tumor volume: tumor volume; comparator: saline as the control group — 2. Results > 2.5. Hyperoside Can Inhibit the Growth of Breast Tumor (S29); 4. Materials and Methods > 4.10. In Vivo Experiment (S85, S86)

Hyperoside 50 mg/kg · 2. Results > 2.5. Hyperoside Can Inhibit the Growth of Breast Tumor (S29); 4. Materials and Methods > 4.10. In Vivo Experiment (S85); Figure 5 legend (S122)

Reduced albuminuria in mice with nephropathy

Animal study · 8-week-old male Balb/c mice (22-28 g body weight); nephropathy; n=6 for each group [3]

In male Balb/c mice with adriamycin-induced nephropathy, Hyperoside was administered by intraperitoneal injection at 20 mg/kg daily for 2 weeks. Albuminuria was reduced compared with the ADR group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Urinary albumin levelsReported result 20 mg/kg hyperoside once every day for 2 weeks: albuminuria was reduced by hyperoside treatment in ADR mice.[3]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
once every day for 2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Hyperoside 20 mg/kgADR group20 mg/kg hyperoside once every day for 2 weeks: albuminuria was reduced by hyperoside treatment in ADR mice.[3]
Hyperoside 20 mg/kg
Model: 8-week-old male Balb/c mice (22-28 g body weight); nephropathy; n=6 for each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Hyperoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Hyperoside prevented renal structural changes and albuminuria in adriamycin mice (S4); MATERIALS AND METHODS > Animals (S51, S52, S53); Figure 1 legend (S94, S95, S96); Figure 2 legend (S103); Figure 3 legend (S111)

Urinary albumin levels: Urinary albumin levels; comparator: ADR group — RESULTS > Hyperoside prevented renal structural changes and albuminuria in adriamycin mice (S4); MATERIALS AND METHODS > Animals (S53); Figure 1 legend (S94)

Hyperoside 20 mg/kg · RESULTS > Hyperoside prevented renal structural changes and albuminuria in adriamycin mice (S4); MATERIALS AND METHODS > Animals (S53)

Specifications

Manufacturer Adooq Bioscience
CAS Number 482-36-0
Formula C21H20O12
Molecular Weight 464.38
Synonyms Hyperin; Quercetin 3-D-galactoside
SMILES
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (195.96 mM)
Water 1 mg/mL (2.15 mM)
Ethanol 1 mg/mL (2.15 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Hyperoside Research References

  1. [1] Wei J, Chai Q, Qin Y, et al. Hyperoside induces ferroptosis in chronic myeloid leukemia cells by targeting NRF2. Mol Med (2024). PMID: 39573995 DOI: 10.1186/s10020-024-01002-7 Source material
  2. [2] Qiu J, Zhang T, Zhu X, et al. Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway. Int J Mol Sci (2019). PMID: 31878204 DOI: 10.3390/ijms21010131 Source material
  3. [3] Chen Z, An X, Liu X, et al. Hyperoside alleviates adriamycin-induced podocyte injury via inhibiting mitochondrial fission. Oncotarget (2017). PMID: 29179476 DOI: 10.18632/oncotarget.21287 Source material

Added to your cart

View Cart Checkout
Loading...